Qinghai Biotech Pharmaceutical Group Limited

As of December 31, 2025, Qinghai Biotech Pharmaceutical Group Limited carries a market capitalization of 352.95M, placing it among publicly traded companies globally. Its enterprise value stands at 251.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Qinghai Biotech Pharmaceutical Group Limited has 100.84M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Qinghai Biotech Pharmaceutical Group Limited maintains a current ratio of 3.98, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Qinghai Biotech Pharmaceutical Group Limited's stock has declined approximately 48.14% over the past 52 weeks. The 50-day moving average sits at 1.85, while the 200-day moving average is 4.73.

As of December 31, 2025, Qinghai Biotech Pharmaceutical Group Limited holds 109.60M in cash and equivalents against 13.46M in total debt, resulting in a net debt position of -109.60M. Total book value stands at 403.38M, with working capital of 192.54M providing operational flexibility.

Qinghai Biotech Pharmaceutical Group Limited's most recent stock split took place on July 9, 2026 with a 50:1 split ratio.